Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What research shows lipitor's impact on oil expenditure?Does lipitor increase muscle cramp risk during exercise?Can i use monistat while on my period?Is cholesterol related protein manufacture altered by lipitor?Has polivy's progression free survival rate improved in recent clinical trials?
See the DrugPatentWatch profile for tigecycline
The antibiotic tigecycline, marketed under the brand name Tygacil, is used to treat various infections. According to DrugPatentWatch.com [1], the tigecycline injection patent was initially assigned to Wyeth (now part of Pfizer) in 2005. However, with the Biologics Price Competition and Innovation Act of 2009 (BPCIA), the United States Patent and Trademark Office (USPTO) was directed to implement a patent term extension (PTE) for certain pharmaceutical and biotechnology products [2]. The PTE aims to extend the lifetime of patents covering pharmaceutical products by up to 5 years. In the case of the tigecycline injection, the patent extension was granted in 2013 by the USPTO [3]. However, it's essential to note that the PTE doesn't guarantee the extension of the patent's expiration date, but rather allows the patent holder to delay its expiration by a specified period. The exact expiration date of the tigecycline injection patent may vary depending on when it was originally filed and granted. To determine the most current information on the patent's status, it's best to refer to the US Patent and Trademark Office (USPTO) database or reputable patent tracking services. To view the patent's assignment and expiration dates, you can visit DrugPatentWatch.com [1], a reliable source for tracking pharmaceutical patents, or consult the official USPTO database. References: [1] DrugPatentWatch.com. (n.d.). Tigecycline Patents. Retrieved from https://www.drugpatentwatch.com/brand/tigecycline [2] U.S. Patent and Trademark Office (USPTO). (n.d.). Patent Term Extension. Retrieved from https://www.uspto.gov/patents-law-resources/patent-term-extension [3] U.S. Patent and Trademark Office (USPTO). (2013). Patent No. US 7,956,292 B2. US Patent Office. Sources: 1. https://www.drugpatentwatch.com/brand/tigecycline 2. https://www.uspto.gov/patents-law-resources/patent-term-extension 3. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7,956,292.PN.&OS=PN/7,956,292&RS=PN/7,956,292
Other Questions About Tigecycline :